Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis

ABSTRACT Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with...

Full description

Saved in:
Bibliographic Details
Published in:Muscle & nerve 2018-08, Vol.58 (2), p.261-269
Main Authors: Raheja, Radhika, Regev, Keren, Healy, Brian C., Mazzola, Maria Antonietta, Beynon, Vanessa, Von Glehn, Felipe, Paul, Anu, Diaz‐Cruz, Camilo, Gholipour, Taha, Glanz, Bonnie I., Kivisakk, Pia, Chitnis, Tanuja, Weiner, Howard L., Berry, James D., Gandhi, Roopali
Format: Article
Language:English
Subjects:
ALS
Alzheimer's disease
Amyotrophic lateral sclerosis
Biomarkers
Diagnosis
disease comparisons
Disease control
longitudinal analysis
Medical prognosis
microRNA
miRNA
Multiple sclerosis
Muscles
Neurodegenerative diseases
Parameter identification
Patients
Ribonucleic acid
RNA
serum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross‐sectional and longitudinal cohorts of ALS patients with clinical parameters. Results: We identified 7 miRNAs (miR‐192‐5p, miR‐192‐3p, miR‐1, miR‐133a‐3p, miR‐133b, miR‐144‐5p, miR‐19a‐3p) that were upregulated and 6 miRNAs (miR‐320c, miR‐320a, let‐7d‐3p, miR‐425‐5p, miR‐320b, miR‐139‐5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR‐136‐3p, miR‐30b‐5p, miR‐331‐3p, miR‐496) correlated positively and change in 1 miRNA (miR‐2110) correlated negatively with changes in clinical parameters in longitudinal analysis. Discussion: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261–269, 2018
ISSN:0148-639X
1097-4598
DOI:10.1002/mus.26106